Analystreport

Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock.

Milestone Pharmaceuticals Inc. - Common Shares  (MIST) 
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am Check Earnings Report